Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 95M | 139M | 140M | 111M | 134M |
| Gross Profit | 65M | 107M | 122M | 100M | 117M |
| Operating Income | 24M | 70M | 84M | 43M | 89M |
| EBITDA | 24M | 71M | 84M | 43M | 90M |
| Net Income | 23M | 59M | 68M | 34M | 69M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.32
+0.23% today
1Y Change
-24.39%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SIGA Technologies, Inc. (SIGA) is a Healthcare stock with a market cap of $330.00M and listed on NASDAQ. The stock last traded around $4.32 and down 24.4% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of -31.8%, EPS growth of -60.2%, a dividend yield of 13.0%. What stands out right now is revenue -31.8%, EPS -60.2%, free cash flow 0.0% with operating margin 25.1% and ROIC 9.0%. The dividend matters to the case here, with a current yield around 13.0%. Valuation is more restrained than many high-expectation growth names at P/E 14.1 and price/sales 3.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SIGA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SIGA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SIGA Max Drawdown
-56.01%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SIGA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$133.7M
+20.7% YoY
FY Net Income
$69.5M
+104.8% YoY
Free Cash Flow
$11.4M
-72.5% YoY
Revenue Growth
-31.8%
EPS Growth
-60.2%
Gross Margin
68.6%
Net Margin
24.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 95M | 139M | 140M | 111M | 134M |
| Gross Profit | 65M | 107M | 122M | 100M | 117M |
| Operating Income | 24M | 70M | 84M | 43M | 89M |
| EBITDA | 24M | 71M | 84M | 43M | 90M |
| Net Income | 23M | 59M | 68M | 34M | 69M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 155M | 155M | 150M | 99M | 103M |
| Total Assets | 219M | 244M | 254M | 195M | 215M |
| Total Liabilities | 21M | 29M | 57M | 25M | 40M |
| Shareholder Equity | 199M | 216M | 197M | 170M | 174M |
| Total Debt | 595K | 547K | 564K | 528K | 467K |
| Net Debt | -154M | -155M | -150M | -98M | -103M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11M
-72.4% YoY
Capital Expenditures
51K
Free Cash Flow
11M
-72.5% YoY
Key ratios
Gross Margin
68.6%
Operating Margin
25.1%
Net Margin
24.6%
ROE
11.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.